Select Equity Group L.P. Purchases Shares of 10,092 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Select Equity Group L.P. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 10,092 shares of the medical equipment provider’s stock, valued at approximately $903,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of LNTH. Kestra Investment Management LLC acquired a new position in Lantheus during the fourth quarter worth about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus in the 4th quarter worth approximately $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new stake in Lantheus during the fourth quarter worth approximately $125,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $81.24 on Friday. The firm’s 50 day moving average price is $97.11 and its two-hundred day moving average price is $93.20. Lantheus Holdings, Inc. has a twelve month low of $75.00 and a twelve month high of $126.89. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the business earned $1.69 EPS. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LNTH has been the topic of several research reports. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.